L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:837035 CAPLUS
DN 139:337787
TI Preparation of novel methoxybenzamides for use in MCH receptor related disorders
IN Hoegberg, Thomas; Bjurling, Anna Emelie; Receveur, Jean-Marie; Little, Paul Brian; Elling, Christian E.; Norregaard, Pia Karina; Ulven, Trond
PA 7TM Pharma A/S, Den.
SO PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003087045	A1	20031023	WO 2003-DK231	20030408
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2482341	A1	20031023	CA 2003-2482341	20030408
	AU 2003226926	A1	20031027	AU 2003-226926	20030408
	EP 1497260	A1	20050119	EP 2003-746255	20030408
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2006235035	A1	20061019	US 2005-510907	20050516 <--
PRAI	DK 2002-519	A	20020409		
	DK 2002-520	A	20020409		
	DK 2002-524	A	20020409		
	DK 2002-1818	A	20021125		
	WO 2003-DK231	W	20030408		

OS MARPAT 139:337787
GI



I



II

AB Title compds. I [wherein A = a linker, e.g. CHR7CONR7, CONR7, OCONR7,

SO2NR7, CHR7NR7CO, NR7COR7, hexahydro-2-oxo-pyrimidine-1,3-diyl, 2-oxoimidazolidine-1,3-diyl, 1,2,4-oxadiazolediyl, 1,3,4-oxadiazolediyl, CH=CH, OCHR7, NR7CHR7, SCHR7, or (un)substituted imidazolediyl or 1,2,4-triazolediyl; Ar = independently (hetero)aryl; R1 = alkoxy; R2 = H, OH, NH2, or alkoxy; COQ = amino-substituted amide; R5 and R6 = independently H, halo, alkoxy, OH, (di)alkylamino, hydroxyalkyl, carboxamido, acyl(amido), CHO, nitrile, alkyl, alkenyl, alkynyl, SMe, (fluoro)alkyl, (fluoro)alkoxy, (fluoro)thioalkoxy, SO2NH2, (di)alkylaminosulfonyl, or alkylsulfonyl; R7 = independently H, alkyl, or alkenyl; R8 = halo, (alkyl)(cyclo)alkyl, alkenyl, alkynyl, (alkyl)(hetero)aryl, (alkyl)heterocyclyl, (aryl)alkoxy, aryloxy, dialkylamino, (di)alkylcarbamoyl, (di)arylcarbamoyl, alkanoyl(amino), aroyl(amino), SMe, (fluoro)alkyl, (fluoro)alkoxy, (fluoro)thioalkoxy, or R6ArB; B = a single bond or connecting moiety; X = H, halo, SMe, CF3, OCF3, SCF3, OMe, alkyl, or alkenyl; and physiol. acceptable salts, complexes, solvates, and prodrugs thereof] were prepared as melanin-concentrating hormone (MCH) receptor modulators. For example, coupling of procainamide with 4-trifluoromethoxyphenyl isocyanate in the presence of TEA in CH2Cl2 gave II (59%). In assays of [125I]-MCH binding and phosphatidylinositol turnover using transiently transfected COS-7 cells or stably transfected CHO cells expressing the human MCH-1 receptor, II exhibited activity with IC50 values of 0.07 μM and 0.29 μM, resp. Administration of II (10 mg/kg i.p.) to male Sprague Dawley rats resulted in a significant reduction of their cumulative food intake over 6 h. Thus, I and their pharmaceutical compns. are useful in the treatment or prevention of obesity, depression, diabetes, bulimia, and other MCH receptor related disorders (no data).

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT